• Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) will present a corporate overview at the H.C.
• Wainwright 26th Annual Global Investment Conference.
• The conference is being held on September 9-11, 2024 at the Lotte New York Palace Hotel.
• Fady Boctor, President and Chief Commercial Officer, will present a corporate overview at the conference.
• The presentation will be available on-demand starting at 7:00 AM ET.
NEW YORK, NY / ACCESSWIRE / September 3, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter ("OTC") drug development programs, announces today that Fady Boctor, President and Chief Commercial Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference. The conference is being held on September 9 - 11, 2024 at the Lotte New York Palace Hotel.
Presentation Date: September 9, 2024
Time: Available on-demand starting at 7:00 AM ET
Investors who wish to listen to the Company's presentation can do so by registering for the conference here: https://hcwevents.com/annualconference/
Mr. Boctor will be available for one-on-one meetings with registered investors of the conference.
About Petros Pharmaceuticals
Petros Pharmaceuticals, Inc. is committed to the goal of becoming a leading innovator in the emerging self-care market driving expanded access to key prescription pharmaceuticals as OTC treatment options. Currently, Petros is pursuing increased access for its flagship prescription ED therapy, STENDRA® (avanafil), via potential OTC designation (see important safety information below.) If ultimately approved by the FDA for OTC access, STENDRA® (avanafil) may be the first in its class to achieve this marketing status, also establishing company know how as a potentially proven platform for other prospective prescription therapeutics.
Contacts:
Investors:
CORE IR
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Jules Abraham
CORE IR
917-885-7378
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.38 |
Daily Change: | 0.01 4.04 |
Daily Volume: | 39,307 |
Market Cap: | US$3.640M |
September 11, 2024 May 21, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB